Search

Author/Creator Muth, John

1. 313 A phase 1 evaluation of tebotelimab, a bispecific PD-1 x LAG-3 DART® molecule, in combination with margetuximab in patients with advanced HER2+ neoplasms. (9th November 2020)

Authors:
Patel, Manish; Luke, Jason; Hamilton, Erika; Chmielowski, Bartosz; Blumenschein, George; Kindler, Hedy; Bahadur, Shakeela; Santa-Maria, Cesar; Koucheki, Janine; Sun, Jichao; Kaul, Sanjeev; Chen, Francine; Zhang, Xiaoyu; Muth, John; Kaminker, Patrick; Moore, Paul; Sumrow, Bradley; Ulahannan, Susanna
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 8(2020)Supplement 3
Page Start:
A193
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. 313 A phase 1 evaluation of tebotelimab, a bispecific PD-1 x LAG-3 DART® molecule, in combination with margetuximab in patients with advanced HER2+ neoplasms. (9th November 2020)

Authors:
Patel, Manish; Luke, Jason; Hamilton, Erika; Chmielowski, Bartosz; Blumenschein, George; Kindler, Hedy; Bahadur, Shakeela; Santa-Maria, Cesar; Koucheki, Janine; Sun, Jichao; Kaul, Sanjeev; Chen, Francine; Zhang, Xiaoyu; Muth, John; Kaminker, Patrick; Moore, Paul; Sumrow, Bradley; Ulahannan, Susanna
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 8(2020)Supplement 3
Page Start:
A340
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗